Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H25FN4O.3ClH |
| Molecular Weight | 465.82 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.Cl.CC(CCN1CCN(CC1)C2=CC=C(F)C=C2)NC(=O)C3=CN=CC=C3
InChI
InChIKey=XWYGMQFKVNQWHV-UHFFFAOYSA-N
InChI=1S/C20H25FN4O.3ClH/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19;;;/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26);3*1H
Niaprazine is a potent and selective antagonist of 5-HT2A and alpha-1 adrenergic receptors. It was used for the treatment of sleep disturbances in children and was investigated for the treatment of sleep disorders in patients with attention-deficit hyperactivity disorder and autistic disorder.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Niaprazine may improve some symptoms of attention-deficit hyperactivity disorder. | 2010-04 |
|
| Drug use in children: cohort study in three European countries. | 2008-11-24 |
|
| Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. | 2006-07 |
|
| Insomnia in children: when are hypnotics indicated? | 2002 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XF51TNX3MK
Created by
admin on Wed Apr 02 11:33:23 GMT 2025 , Edited by admin on Wed Apr 02 11:33:23 GMT 2025
|
PRIMARY | |||
|
166528
Created by
admin on Wed Apr 02 11:33:23 GMT 2025 , Edited by admin on Wed Apr 02 11:33:23 GMT 2025
|
PRIMARY | |||
|
DTXSID90955974
Created by
admin on Wed Apr 02 11:33:23 GMT 2025 , Edited by admin on Wed Apr 02 11:33:23 GMT 2025
|
PRIMARY | |||
|
34426-53-4
Created by
admin on Wed Apr 02 11:33:23 GMT 2025 , Edited by admin on Wed Apr 02 11:33:23 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
